Evidence map›Paper›PMID 41659627›Full record

ArticlebioRxiv : the preprint server for biology2026

Modeling HIV infection, treatment, rebound, and intervention in human immune organoids.

Sarah A Sackey, Jacob E Schrum, Uma M Mangalanathan, Rachel S Fish, Elsa Sola, Ahmad Selehi, Ruoxi Pi, Jerome A Zack, Jocelyn T Kim, Dara A Lehman and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah A SackeyStanford Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
Jacob E SchrumDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Uma M MangalanathanDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Rachel S FishDivision of Human Biology, Fred Hutch Cancer Center, Seattle, WA, USA.
Elsa SolaInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Ahmad SelehiDonor Network West, San Ramon, California, USA.
Ruoxi PiDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Jerome A ZackDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Jocelyn T KimDepartment of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, 90095, USA.
Dara A LehmanDivision of Human Biology, Fred Hutch Cancer Center, Seattle, WA, USA.
Mark M DavisStanford Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
Catherine A BlishStanford Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.

Funding

MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
EMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8M
Natural killer cell engineering to target the HIV reservoirR01AI161803 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BLISH, CATHERINE A, ZACK, JEROME A. · 2021 to 2025
$3.8M
High resolution inflammatory networks induced by HIV reservoirs in adolescentsR01AI183381 · NIAID · STANFORD UNIVERSITY · PI Catherine A Blish · 2024 to 2026
$2.4M
Multiparametric deep tissue microscope for in vivo and in vitro imagingS10OD032300 · OD · STANFORD UNIVERSITY · PI O'BRIEN, LUCY ERIN · 2022 to 2022
$600k
NIAID NIH HHS R01 AI161803NIAID NIH HHS R01 AI183381NIAID NIH HHS T32 AI007290NIAID NIH HHS T32 AI007502NIH HHS S10 OD032300
6 · The paper itself

Abstract

Targeting the HIV-infected reservoir in lymphoid tissues (LT) will be critical to developing a cure for people living with HIV (PLWH). LT explants used to study HIV infection enable the evaluation of human-specific disease progression and treatment response; however, their short lifespan makes it challenging to assess long-term treatment interventions. We therefore established an immune organoid model of HIV infection using human tonsil or spleen cells, demonstrating productive HIV infection and viral integration into CD4

Identifiers

PMID41659627
PMCPMC12873895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.